Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 12851 | 814 | 35.5 | 86% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | C 11 CHOLINE PET CT | Author keyword | 47 | 86% | 3% | 24 |
| 2 | C 11 CHOLINE | Author keyword | 40 | 62% | 5% | 42 |
| 3 | CHOLINE PET | Author keyword | 27 | 83% | 2% | 15 |
| 4 | CHOLINE PET CT | Author keyword | 23 | 86% | 1% | 12 |
| 5 | F 18 CHOLINE | Author keyword | 17 | 63% | 2% | 17 |
| 6 | FLUOROCHOLINE | Author keyword | 15 | 68% | 2% | 13 |
| 7 | F 18 FLUOROCHOLINE | Author keyword | 14 | 57% | 2% | 16 |
| 8 | PET CT LINZ | Address | 13 | 69% | 1% | 11 |
| 9 | C 11 ACETATE | Author keyword | 9 | 33% | 3% | 21 |
| 10 | SALVAGE LYMPH NODE DISSECTION | Author keyword | 8 | 100% | 1% | 5 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | C 11 CHOLINE PET CT | 47 | 86% | 3% | 24 | Search C+11+CHOLINE+PET+CT | Search C+11+CHOLINE+PET+CT |
| 2 | C 11 CHOLINE | 40 | 62% | 5% | 42 | Search C+11+CHOLINE | Search C+11+CHOLINE |
| 3 | CHOLINE PET | 27 | 83% | 2% | 15 | Search CHOLINE+PET | Search CHOLINE+PET |
| 4 | CHOLINE PET CT | 23 | 86% | 1% | 12 | Search CHOLINE+PET+CT | Search CHOLINE+PET+CT |
| 5 | F 18 CHOLINE | 17 | 63% | 2% | 17 | Search F+18+CHOLINE | Search F+18+CHOLINE |
| 6 | FLUOROCHOLINE | 15 | 68% | 2% | 13 | Search FLUOROCHOLINE | Search FLUOROCHOLINE |
| 7 | F 18 FLUOROCHOLINE | 14 | 57% | 2% | 16 | Search F+18+FLUOROCHOLINE | Search F+18+FLUOROCHOLINE |
| 8 | C 11 ACETATE | 9 | 33% | 3% | 21 | Search C+11+ACETATE | Search C+11+ACETATE |
| 9 | SALVAGE LYMPH NODE DISSECTION | 8 | 100% | 1% | 5 | Search SALVAGE+LYMPH+NODE+DISSECTION | Search SALVAGE+LYMPH+NODE+DISSECTION |
| 10 | BIOCHEMICAL RELAPSE | 7 | 32% | 2% | 18 | Search BIOCHEMICAL+RELAPSE | Search BIOCHEMICAL+RELAPSE |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | C 11 CHOLINE PET CT | 123 | 74% | 11% | 91 |
| 2 | F 18 CHOLINE PET CT | 106 | 91% | 5% | 43 |
| 3 | C 11 CHOLINE PET | 66 | 69% | 7% | 56 |
| 4 | TOMOGRAPHY COMPUTERIZED TOMOGRAPHY | 62 | 92% | 3% | 24 |
| 5 | C 11 ACETATE PET | 38 | 78% | 3% | 25 |
| 6 | C 11 CHOLINE | 36 | 58% | 5% | 42 |
| 7 | F 18 FLUOROCHOLINE | 36 | 63% | 4% | 36 |
| 8 | ANTIGEN RELAPSE | 29 | 75% | 3% | 21 |
| 9 | 18FLUORINE LABELED DEOXYGLUCOSE | 21 | 73% | 2% | 16 |
| 10 | EMISSION TOMOGRAPHY COMPUTERIZED TOMOGRAPHY | 15 | 82% | 1% | 9 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
|---|---|---|---|---|
| Contemporary Role of Salvage Lymphadenectomy in Patients with Recurrence Following Radical Prostatectomy | 2015 | 3 | 59 | 66% |
| The Role of 11C-Choline and 18F-Fluorocholine Positron Emission Tomography (PET) and PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis | 2013 | 39 | 72 | 86% |
| Metastasis-directed Therapy of Regional and Distant Recurrences After Curative Treatment of Prostate Cancer: A Systematic Review of the Literature | 2015 | 3 | 40 | 48% |
| Choline PET or PET/CT and Biochemical Relapse of Prostate Cancer A Systematic Review and Meta-Analysis | 2013 | 36 | 55 | 73% |
| F-18-fluorocholine for prostate cancer imaging: a systematic review of the literature | 2012 | 45 | 57 | 75% |
| The Role of Choline Positron Emission Tomography/Computed Tomography in the Management of Patients with Prostate-Specific Antigen Progression After Radical Treatment of Prostate Cancer | 2011 | 77 | 43 | 63% |
| Meta-analysis of C-11-choline and F-18-choline PET/CT for management of patients with prostate cancer | 2014 | 8 | 79 | 99% |
| Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates | 2013 | 23 | 73 | 64% |
| F-18-Choline, C-11-choline and C-11-acetate PET/CT: comparative analysis for imaging prostate cancer patients | 2013 | 13 | 90 | 90% |
| Choline PET and PET/CT in Primary Diagnosis and Staging of Prostate Cancer | 2012 | 18 | 70 | 74% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | PET CT LINZ | 13 | 69% | 1.4% | 11 |
| 2 | HAMAMATSU QUEENS PET IMAGING | 5 | 63% | 0.6% | 5 |
| 3 | MOL BIOIMAGING | 5 | 38% | 1.2% | 10 |
| 4 | AZIENDA OSPED UNIV BOLOGNA | 4 | 67% | 0.5% | 4 |
| 5 | UNIV MED ROSTOCK | 4 | 56% | 0.6% | 5 |
| 6 | OU NUCL MED | 3 | 100% | 0.4% | 3 |
| 7 | PAD 30 | 3 | 100% | 0.4% | 3 |
| 8 | GE IMANET | 2 | 67% | 0.2% | 2 |
| 9 | NUCL MED RADIOL MED PHYS | 2 | 67% | 0.2% | 2 |
| 10 | OU MED PHYS | 2 | 67% | 0.2% | 2 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000173845 | PELVIC LYMPH NODE DISSECTION//EXTENDED PELVIC LYMPH NODE DISSECTION//LYMPH NODE INVASION |
| 2 | 0.0000153125 | VIRTUAL CYSTOSCOPY//BLADDER NEOPLASMS STAGING//BLADDER NEOPLASMS CT |
| 3 | 0.0000141016 | F 18 FLT//F 18FLT//FLT |
| 4 | 0.0000140356 | F 18 FLUORIDE//BONE SCINTIGRAPHY//BONE SCAN INDEX |
| 5 | 0.0000136710 | C 11 METHIONINE//O 2 F 18FLUOROETHYL L TYROSINE//FET PET |
| 6 | 0.0000129976 | ATSUCHI MEM RADIOL//HAMAMATSU MED IMAGING//PET ANGIOGRAPHY |
| 7 | 0.0000112067 | CANAVAN DISEASE//PROSTATE SPECIFIC MEMBRANE ANTIGEN//PSMA |
| 8 | 0.0000112060 | FOCAL THERAPY//TARGETED BIOPSY//PROSTATE BIOPSY |
| 9 | 0.0000103206 | LYMPHATIC SYSTEM MR//LYMPHOGRAPHY//INTERSTITIAL MR LYMPHOGRAPHY |
| 10 | 0.0000097020 | GIRENTUXIMAB//G250//MONOCLONAL ANTIBODY CG250 |